Clinical Pharmacokinetics | 2011(50) articles
- Does Olanzapine Warrant Clinical Pharmacokinetic Monitoring in Schizophrenia?
- Structural Models Describing Placebo Treatment Effects in Schizophrenia and Other Neuropsychiatric Disorders
- Influence of Cytochrome P450 3A5 (CYP3A5) Genetic Polymorphism on the Pharmacokinetics of the Prolonged-Release, Once-Daily Formulation of Tacrolimus in Stable Renal Transplant Recipients
- Lidocaine (Lignocaine) Dosing Regimen Based upon a Population Pharmacokinetic Model for Preterm and Term Neonates with Seizures
- Asenapine Pharmacokinetics in Hepatic and Renal Impairment